Tags
- 3
- 4
- 4 Times
- A
- Address space
- Administration
- Agriculture in the United States
- ALS
- Amyotrophic lateral sclerosis
- An
- Application
- Approved
- Assessment
- Assistance
- Ataxia
- Based on
- Benefit
- Bioavailability
- Capacity
- Care
- Cause
- Children
- Clinic
- Clinical
- Clinical trial
- Clinical Trials
- Community
- Continued
- Cure
- Daily activities
- David Geffen
- David Geffen School of Medicine at UCLA
- Deference
- Defined
- Delay
- Destroy
- Development
- Disease
- Disease progression
- Dosing
- Drug
- Drug discovery
- Drugs
- End
- Estimation
- Europe
- Failure
- Fast Track
- Fatal
- FDA
- Fighting
- Food
- Food and Drug Administration
- Functional
- Geffen
- Genetic
- Genetic cause
- Genotype
- Greater
- Heterogeneity
- Hopeful
- Independence
- Inherit
- Intelligence
- Kind of
- Known
- Lack
- Lateral
- Leaving
- Liverpool Sound Collage
- Matched
- Medicine
- Mental
- Modified
- Moment
- Most
- Motor neuron
- Motor neuron disease
- Movement
- Mutation
- Mutations
- Nature
- Neurogenetics
- Neurological disorder
- Neurology
- Neuron
- New
- New drug application
- New trial
- No
- No Cure
- Number
- Orphan
- Orphan drug
- Over
- Parent
- Parent company
- Participation
- Patient
- Perlman
- Persistence
- Pfizer
- Pharmaceutical drug
- Phase
- Phase 3
- Phase 3 trial
- Physical
- Physical control
- Positive
- Press release
- Priority
- Priority review
- Prodrug
- Progression
- Progressive
- Progressive disease
- Quality
- Quality of life
- Real World
- Refused
- Regulator
- Result
- Retain
- Riluzole
- SCA
- Scale
- School
- School of Medicine
- Sclerosis
- Set
- Setback
- Setbacks
- Sets
- Severity
- Shown
- Some
- Speak
- Speed
- Spinocerebellar ataxia
- Spinocerebellar tract
- Spun
- Statistical hypothesis testing
- Survival
- Susan Perlman
- Symptom
- Symptoms
- The David
- The Drugs
- The end
- Then
- Therapy
- The trial
- This Condition
- This week
- Treat
- Treating
- Trial
- Trials
- Type III
- UCLA
- Walk
- When
- Who